Neuroprotection by Caffeine and A2A Adenosine Receptor Inactivation in a Model of Parkinson's Disease

  title={Neuroprotection by Caffeine and A2A Adenosine Receptor Inactivation in a Model of Parkinson's Disease},
  author={Jiang Fan Chen and Kui Xu and Jacobus P. Petzer and Roland G. W. Staal and Yuehang Xu and Mark Beilstein and Patricia K. Sonsalla and Kay P. Castagnoli and Neal Castagnoli and Michael A Schwarzschild},
  journal={The Journal of Neuroscience},
  pages={RC143 - RC143}
Recent epidemiological studies have established an association between the common consumption of coffee or other caffeinated beverages and a reduced risk of developing Parkinson's disease (PD). To explore the possibility that caffeine helps prevent the dopaminergic deficits characteristic of PD, we investigated the effects of caffeine and the adenosine receptor subtypes through which it may act in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin model of PD. Caffeine, at doses… 

Figures from this paper

Estrogen Prevents Neuroprotection by Caffeine in the Mouse 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease
It is suggested that estrogen can occlude and thereby prevent the neuroprotective effect of caffeine in a model of PD neurodegeneration, supporting a biological basis for the interaction between estrogen and caffeine in modifying the risk of PD.
Effects of adenosine receptor antagonists in MPTP mouse model of Parkinson’s disease: mitochondrial DNA integrity
Therapy with caffeine or KW-6002 not only led to the reversibility of movement dysfunction and increased the concentrations of dopamine and ATP levels, but also ameliorates the dopaminergic neuron loss and restored the mtDNA and nDNA integrity.
Effect of Adenosine A2A Receptor Antagonists on l-DOPA-Induced Hydroxyl Radical Formation in Rat Striatum
A2A antagonists, used as a supplement of l-DOPA therapy, depending on the dose used, may have a beneficial or adverse effect on ongoing neurodegenerative processes and accompanying oxidative stress.
Adenosine A2A receptor antagonists: Potential therapeutic and neuroprotective effects in parkinson’s disease
Positive results emerged from studies showing neuroprotective properties of adenosine A2A antagonists in animal models of cerebral ischemia and excitotoxicity, as well as in the (1-methy1-4-pheny1-1-2,3,6-tetrahydropyridine) (MPTP) model of PD.
Blockade of Striatal Adenosine A2A Receptor Reduces, through a Presynaptic Mechanism, Quinolinic Acid-Induced Excitotoxicity: Possible Relevance to Neuroprotective Interventions in Neurodegenerative Diseases of the Striatum
The adenosine A2A receptor antagonist SCH 58261 has neuroprot protective effects, although only at low doses, in an excitotoxic rat model of HD, and the inhibition of QA-evoked glutamate outflow seems to be the major mechanism underlying the neuroprotective effects.


Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys
Adenosine A2A receptor antagonists have antiparkinsonian effects of their own with a reduced propensity to elicit dyskinesias and might therefore be useful agents in the treatment of PD.
Protection against methamphetamine-induced neurotoxicity to neostriatal dopaminergic neurons by adenosine receptor activation.
Results indicate that activation of A1 receptors can protect against METH-induced neurotoxicity in mice, and concurrent administration of cyclopentyladenosine, an adenosine A1 receptor agonist, attenuated the Meth-induced neurochemical changes.
Protection Against Acute MPTP‐Induced Dopamine Depletion in Mice by Adenosine A1 Agonist
Neurochemical data suggest that the A1 agonist CHA is potentially useful as a neuroprotective agent against MPTP‐induced toxicity.
Adenosine A2A Receptors and Neuroprotection
The great advance recently made with the discovery of selective A2A receptor ligands provides increasing information on the function of A 2A receptors and opens new perspectives for treatment of neurological disorders.
Effects of Caffeine on Monoamine Neurotransmitters in the Central and Peripheral Nervous System
This review focuses primarily on the effects of caffeine on the monoamine neurotransmitters, and on caffeine’s proposed effects on adenosine receptors, one possible route by which the methylxanthine exerts its actions on catecholamine neurons (as well as other cells).
Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice.
Study on the metabolism of MPTP after peripheral administration revealed that there was a significant (P less than .01) positive correlation between the relative sensitivity of the mouse strains to MPTP and their neostriatal MPP+ content after MPTP administration.
Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice.
It is suggested that pretreatment with nimodipine--during the observation period of 7 days--protects against MPTP-induced neurotoxicity in mice at the nigral ('cell body'), but not at the synaptic striatal level.
Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease.